In randomised trials on myo-inositol in pregnancy to prevent or treat gestational diabetes, myo-inositol showed a significant reduction in levels of fasting and postprandial blood glucose, HOMA-IR and insulinaemia.19–21 We found a reduction in insulin and HOMA-IR in the intervention arm vs control, indicating a potentially increased insulin sensitivity with myo-inositol. This evidence concerns the gene INS and gestational diabetes.